HCW Biologics Inc. (HCWB)
- Previous Close
1.1700 - Open
1.1900 - Bid --
- Ask --
- Day's Range
1.1200 - 1.2041 - 52 Week Range
0.9100 - 2.3200 - Volume
25,961 - Avg. Volume
17,422 - Market Cap (intraday)
42.362M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
www.hcwbiologics.comRecent News: HCWB
Performance Overview: HCWB
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HCWB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HCWB
Valuation Measures
Market Cap
42.74M
Enterprise Value
45.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.29
Price/Book (mrq)
3.17
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.68%
Return on Equity (ttm)
-98.23%
Revenue (ttm)
2.84M
Net Income Avi to Common (ttm)
-24.99M
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.6M
Total Debt/Equity (mrq)
47.93%
Levered Free Cash Flow (ttm)
-15.29M
Research Analysis: HCWB
Company Insights: HCWB
HCWB does not have Company Insights